Cassava Sciences drops on delay for epilepsy study
Source: SeekingAlpha
2025-12-19 07:27:38 ET
More on Cassava Sciences
- Cassava Sciences: Fundamentals Update After Big Move On Insider Purchases
- Cassava Sciences hit with FDA request for more data on simufilam trial
- Cassava Sciences spikes as CEO buys stock
- Seeking Alpha’s Quant Rating on Cassava Sciences
- Historical earnings data for Cassava Sciences
Read the full article on Seeking Alpha
For further details see:
Cassava Sciences drops on delay for epilepsy study
Cassava Sciences Inc.
NASDAQ: SAVA
SAVA Trading
15.14% G/L:
$2.395 Last:
1,546,293 Volume:
$2.19 Open:
SAVA Latest News
April 15, 2026 08:00:00 am
Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam DataMarch 12, 2026 08:00:00 am
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsSAVA Stock Data
$106,035,832
47,148,506
2.07%
34
N/A
Biotechnology & Life Sciences
Healthcare
US
Austin
